We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Amarin (AMRN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amarin is a member of the Medical sector. This group includes 979 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amarin is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 50.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AMRN has returned about 56% since the start of the calendar year. At the same time, Medical stocks have lost an average of 6.1%. This means that Amarin is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Bayer Aktiengesellschaft (BAYRY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 63.1%.
The consensus estimate for Bayer Aktiengesellschaft's current year EPS has increased 6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Amarin belongs to the Medical - Biomedical and Genetics industry, a group that includes 489 individual companies and currently sits at #144 in the Zacks Industry Rank. On average, stocks in this group have gained 0.2% this year, meaning that AMRN is performing better in terms of year-to-date returns.
Bayer Aktiengesellschaft, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 10-stock industry is ranked #90. The industry has moved -3.7% so far this year.
Investors with an interest in Medical stocks should continue to track Amarin and Bayer Aktiengesellschaft. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Amarin (AMRN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amarin is a member of the Medical sector. This group includes 979 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amarin is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 50.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AMRN has returned about 56% since the start of the calendar year. At the same time, Medical stocks have lost an average of 6.1%. This means that Amarin is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Bayer Aktiengesellschaft (BAYRY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 63.1%.
The consensus estimate for Bayer Aktiengesellschaft's current year EPS has increased 6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Amarin belongs to the Medical - Biomedical and Genetics industry, a group that includes 489 individual companies and currently sits at #144 in the Zacks Industry Rank. On average, stocks in this group have gained 0.2% this year, meaning that AMRN is performing better in terms of year-to-date returns.
Bayer Aktiengesellschaft, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 10-stock industry is ranked #90. The industry has moved -3.7% so far this year.
Investors with an interest in Medical stocks should continue to track Amarin and Bayer Aktiengesellschaft. These stocks will be looking to continue their solid performance.